Clinical trials: Erythropoietin
Angiogenesis, Ischemic Stroke
Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits
Neovascularization Induced by Mechanical Barrier disrUption and Systemic erythropoietin in patients with cerebral perfusion deficits (NIMBUS trial)
- Trial name
- NIMBUS (NCT02603406)
- Testing
- erythropoietin
- Volunteers
- 44 people
- Sponsor
- Ajou University School of Medicine
Thalassemia Intermedia
Therapeutic Effect and Safety of Combined Hydroxyurea With Recombinant Human Erythropoietin.
The study hypothesis that treatment with Erythropoietin (EPO) combined with Human Erythropoietin (HUO) therapy will result in hematologic improvement in thalassemia intermedia patients.
- Trial name
- NCT01624038
- Testing
- Hydroxyurea ,Epiao, hydroxyurea, blood transfusion
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Ain Shams University
Renal Effects
Renal Effects of Erythropoietin in Humans
Erythropoietin (EPO) is a glycoprotein produced mainly in the kidney. After its release to the bloodstream EPO binds to its receptor predominantly located within the bone marrow where erythropoiesis is stimulated.
- Trial name
- EPO 2012 (NCT01584921)
- Testing
- Erythropoietin (Epoetin-beta, NeoRecormon®)
- Where
- Denmark
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
End Stage Renal Failure, Anaemia
Effectiveness of a Biosimilar Epoetin Alfa in Stable 'End Stage Renal Failure'
This is a prospective, observational, non-inferior study in ESRF patients stable on Eprex who are switched to a Biosimilar Epoetin Alfa. Study plans to recrut 44 patients.
- Trial name
- NCT02341547
- Testing
- a Biosimilar Epoetin Alfa
- Volunteers
- 44 people
- Sponsor
- Penang Hospital, Malaysia
Substance Abuse Problem
Identification of New Serum Markers for Detection of Abuse With Erythropoietin
Epo increases red blood cell production and hence the amount of oxygen that can be transported around the body. It is shown that prolonged use of synthetic Epo (rHuEpo) leads to an increase in the period of time a given physical…
- Trial name
- NCT01320449
- Testing
- recombinant human erythropoietin, Training
- Where
- 2 sites in Denmark
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Anemia, Kidney Transplantation
An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant
This observational study will investigate efficacy and safety of methoxy polyethyleneglycol-epoetin beta in participants with a kidney transplant. Data of each participant will be collected over 15 months of Mircera therapy.
- Trial name
- NCT02538107
- Testing
- Methoxy-polyethyleneglycol epoetin beta
- Where
- Germany
- Volunteers
- 290 people
- Sponsor
- Hoffmann-La Roche
Intraventricular Hemorrhage of Prematurity
Safety of Erythropoietin and Melatonin for Very Preterm Infants With Intraventricular Hemorrhage
Very preterm infants are prone to numerous medical complications with lifelong impact. Amongst the most serious neurologically are white matter injury (WMI), intraventricular hemorrhage (IVH) and the subsequent progression to…
- Trial name
- SCEMPI (NCT05617833)
- Testing
- MLT+EPO
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Johns Hopkins University
Chronic Kidney Disease, End Stage Renal Disease
Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease
The purpose of this open-label extension study is to evaluate long-term efficacy and safety of roxadustat in maintaining hemoglobin (Hb) in participants with dialysis and non-dialysis chronic kidney disease (CKD) who have…
- Conditions
- Chronic Kidney Disease, End Stage Renal Disease, Anemia
- Trial name
- NCT01630889
- Testing
- Roxadustat
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 15 people
- Sponsor
- Kyntra Bio
Chronic Kidney Disease
An Observational Study of Case Managed Versus Non-case Managed Initiation of Hemodialysis
The purpose of the study is to compare the 90 day and 12 month composite end point of death (all-cause mortality) and hospitalization in incident hemodialysis patients randomized to receive support from a dedicated case manager…
- Trial name
- PROSTARRT (NCT01613404)
- Testing
- No intervention
- Where
- 14 sites in Canada
- Volunteers
- 248 people
- Sponsor
- Janssen Inc.
Renal Failure Chronic, Anemia
Predictors of Response to Iron and Erythropoietin Stimulating Agents
The purpose of the study is to identify predictors of treatment response. This involves collected baseline clinical parameters and bloods for biochemical parameters prior to administering the study treatment.
- Trial name
- PRIME (NCT03658876)
- Testing
- Iron Sucrose Solution for Injection, Epoetin Beta
- Volunteers
- 197 people
- Sponsor
- Imperial College London
Chemotherapy-induced Symptomatic Anaemia, Solid Tumours
Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
The purpose of this study is to observe correction of haemoglobin (Hb) levels in patients receiving chemotherapy as a consequence of a solid tumour, a malignant lymphoma or a multiple myeloma and who are treated with Retacrit™.
- Conditions
- Chemotherapy-induced Symptomatic Anaemia, Solid Tumours, Malignant Lymphomas, Multiple Myeloma
- Trial name
- NCT01626547
- Where
- 39 sites in Germany
- Volunteers
- 291 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Kidney Failure, Chronic
The Clinical Evaluation of the Dose of Erythropoietins Trial
Anaemia is a risk factor for death, cardiac-cerebrovascular events and poor quality of life in patients with chronic kidney disease (CKD). Erythropoietin Stimulating Agents (ESAs) are the most used treatment option.
- Trial name
- CEDOSE (NCT00827021)
- Testing
- Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.
- Where
- 41 sites in Italy
- Volunteers
- 656 people
- Sponsor
- Giovanni FM Strippoli, MD
Anemia, Kidney Failure
Levocarnitine for Reducing ESA Requirements in Hemodialysis Patients With Renal Anemia
Renal anemia is common in people receiving long-term hemodialysis and is usually treated with erythropoiesis-stimulating agents (ESAs).
- Conditions
- Anemia, Kidney Failure, End-Stage Renal Disease, Renal Dialysis
- Trial name
- L-CAR-ESA (NCT07160452)
- Testing
- Levocarnitine Injection, Usual ESA-Based Anemia Care
- Volunteers
- 94 people
- Sponsor
- Shaikh Zayed Hospital, Lahore
Anemia, Transfusion
Perioperative Iron With Erythropoietin in Bilateral Total Knee Replacement Arthroplasty (TKRA)
The object of this study is to evaluate whether low dose intravenous iron and erythropoietin (Epo) can decrease transfusion requirement after the bilateral TKRA.
- Trial name
- SNUBH (NCT01012063)
- Testing
- iron sucrose, erythropoietin-β, normal saline
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Seoul National University Bundang Hospital
Anemia
Intravenous (IV) Iron vs. No Iron as the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy
To assess the change in hemoglobin levels when iron sucrose was added to a regimen of weekly, fixed doses of erythropoietin in patients who had or had not responded to erythropoietin therapy alone.
- Trial name
- NCT00236951
- Testing
- iron sucrose injection USP, stable erythropoietin therapy
- Volunteers
- 224 people
- Sponsor
- American Regent, Inc.
Myelodysplastic Syndromes
Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes
This trial is designed to explore a modified dose and schedule of azacitidine in order to more effectively address the needs of patients with low-risk myelodysplastic syndromes (MDS), i.e., to alter the natural history of the…
- Trial name
- NCT00379912
- Testing
- Azacitidine, Erythropoietin, Azacitidine (Monotherapy)
- Where
- 9 sites in United States
- Volunteers
- 15 people
- Sponsor
- Larry Cripe, MD
Cancer, Anemia
An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks
The purpose of this study is to determine the effectiveness and safety of PROCRIT (Epoetin alfa) at a starting dose of 60,000 Units (U) once every week (QW) to a target hemoglobin (Hb) of 12 g/dL (Initiation Phase), followed by a…
- Trial name
- NCT00338416
- Testing
- Epoetin alfa
- Volunteers
- 115 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Human Volunteers
Effects of Micro-dose and Low-dose Recombinant Human Erythropoietin on Mitochondrial Function and Cognitive Performance
A recent study by Plenge et al. revealed that rhEpo treatment enhances skeletal muscle mitochondrial respiratory capacity in humans indicating a muscle ergogenic effect of rhEpo on aerobic metabolism.
- Trial name
- NCT03093506
- Testing
- Low-dose rhEpo, Micro-dose rhEpo
- Where
- Denmark
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bispebjerg Hospital
Breast Cancer
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer.
- Trial name
- NCT00014222
- Testing
- epoetin alfa, filgrastim, cyclophosphamide
- Where
- 78 sites in United States, Canada
- Volunteers
- 2,104 people
- Sponsor
- NCIC Clinical Trials Group
Iron Deficiency Anemia
2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.
This is a phase 3 clinical investigation. Patients who meet the eligibility criteria and provide signed informed consent will be randomized to receive one of two levels of Ferrlecit or oral iron in a 1:1:1 ratio.
- Trial name
- NCT00223977
- Testing
- Sodium Ferric Gluconate Complex, Oral Iron
- Where
- 43 sites in United States, Bulgaria and 6 more
- Volunteers
- 146 people
- Sponsor
- Watson Pharmaceuticals